Mitotech

Mitotech

Core business

Mitotech S.A. is a Luxembourg-based clinical stage biotechnology company developing novel drugs for treatment of predominantly age-related disorders. The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria directed cardiolipin peroxidation inhibitors. Company’s lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases.

Products & services

Company’s most clinically advanced drug formulation is Visomitin – ophthalmic solution of SkQ1 developed for several age-related eye disorders, including Dry Eye Disease, where Mitotech reached Phase 3 clinical stage in the U.S. Mitotech is also approaching clinical stage of development of its oral drug formulation for treatment of Multiple Sclerosis, Alzheimer’s Disease and other disorders.



Print this page Send by email
Mitotech

CEO

Natalia Perekhvatova

Creation date

09/2010

Employees

5

Organisation type

SME

Trading area

International

Address

42 rue de la Vallee
Luxembourg L-2661
Website

Contact


Email

Les cookies participent au bon fonctionnement de ce site internet. En utilisant ce dernier, vous acceptez l’utilisation des cookies. En savoir plus